Brooks Laboratories board meets on May 29 to consider FY26 results

Brooks Laboratories Limited has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The primary agenda of the meeting is to consider and approve the audited standalone and consolidated financial results of the company for the quarter and year ended March 31, 2026.

Board Meeting Agenda

The board will review the financial performance for the fiscal year ending March 31, 2026. This meeting is being convened in compliance with Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Trading Window Closure

Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the company's Code of Conduct for Prevention of Insider Trading, the trading window for all Directors, Designated Persons, and their immediate relatives has been closed since April 1, 2026. This closure applies to dealing in the securities of the company.

The trading window will remain closed until 48 hours after the declaration of the audited financial results. This measure is intended to ensure compliance with regulatory standards regarding insider trading during the period of financial result announcements.

The intimation regarding the board meeting was officially communicated to the stock exchanges on May 22, 2026.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+5.00%	+28.44%	-7.92%	-40.84%	-53.69%	-42.29%

In a regulatory filing dated May 14, 2026, brooks laboratories disclosed that Brooks Steriscience Limited (BSL), a joint venture and associate of the company, has opted not to proceed with a previously announced composite scheme of arrangement and amalgamation. The decision was reached at a meeting of BSL's Board of Directors held on the same date, with the board citing the best interest of all stakeholders as the basis for withdrawing from the transaction in its current form.

Background of the Proposed Scheme

The development is a follow-up to an earlier intimation issued on February 6, 2026, which had detailed the in-principle approval granted by the National Stock Exchange of India Limited and BSE Limited to Onesource Specialty Pharma Limited for the proposed composite scheme. The scheme had envisaged a merger by absorption involving multiple entities, as outlined below:

Parameter:	Details
Type of Transaction:	Composite Scheme of Arrangement and Amalgamation (Merger by Absorption)
Entities Involved:	Steriscience Specialties Private Limited, Brooks Steriscience Limited, Steriscience Pte. Limited, Strides Pharma Services Private Limited, and Onesource Specialty Pharma Limited
In-Principle Approval Date:	February 6, 2026
Approving Exchanges:	National Stock Exchange of India Limited and BSE Limited
Board Decision Date:	May 14, 2026
Decision:	Not to pursue the transaction in the current form

Board Decision and Stakeholder Considerations

BSL's Board of Directors, after deliberating on the proposed transaction at its meeting on May 14, 2026, resolved not to proceed with the scheme in its current form. The board's decision was communicated to Brooks Laboratories, which subsequently notified the stock exchanges in compliance with applicable disclosure requirements. The filing was signed by Krutika Rane, Company Secretary and Compliance Officer of Brooks Laboratories Limited, bearing Membership No. 66310.

Regulatory Disclosure

The intimation was submitted to both BSE Limited and the National Stock Exchange of India Limited as part of the company's obligations under Regulation 30. Brooks Laboratories has requested the exchanges to take the update on record. No further details regarding the reasons for the withdrawal or any revised transaction structure were provided in the filing.